TrialNerd_Beth said:Orforglipron is the more interesting oral story because it is not a peptide at all.
I do not accept that the fasting window is a minor inconvenience. Adherence data on daily orals with timing requirements is consistently worse than weekly injections, and a drug you take imperfectly is a lower dose than the one on the box.
One concrete data point for the thread. One practical note: write down what you did and when, before you need it. Reconstructing a timeline from memory three months later is how people end up unable to answer the one question that would have resolved it.
BethLabQueen said:I do not accept that the fasting window is a minor inconvenience.
There is a second half to this that has not been said yet. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after tommy_boulder’s answer:
How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?
Closing the loop on my own question.
Update — I went back to the injectable. Not because the tablet did not work, but because the fasting window and my mornings were never going to agree.